Unilife Corp

Unilife — Q2 FY2013 Earnings Presentation

19 slides from Unilife's earnings presentation, Feb 12, 2013

  1. Slide 1: Fiscal Year 2013 2nd Quarter Earnings Call

    NASDAQ (UNIS) and ASX (UNS) Fiscal Year 2013 2nd Quarter Earnings Call February 11, 2013

  2. Slide 2: Cautionary Note Regarding Forward-Looking Statements

    This presentation contains forward looking statements under the safe harbor provisions of the US securities laws. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-lo

  3. Slide 3: Opening Statement CEO Alan Shortall

    Opening Statement CEO Alan Shortall NASDAQ (UNIS) and ASX (UNS)

  4. Slide 4: Dr. Ramin Mojdeh, EVP and COO

    Dr. Ramin Mojdeh Unilife EVP and COO NASDAQ (UNIS) and ASX (UNS)

  5. Slide 5: A Selection of our Active Programs

    A Selection of our Active Programs A Selection of our Active Programs February 11, 2013

  6. Slide 6: Typical Steps in a Customer Program

    Typical Steps in a Customer Program February 11, 2013

  7. Slide 7: Investing in R&D for Long-term Growth

    Investing in R&D for Long-term Growth Broad commercial pipeline driving multiple programs for multiple devices with multiple customers Requires large and sustained R&D investment upfront Upfront investment generate significant returns over time Our investment in R&D covers many areas Customization o

  8. Slide 8: A Rapidly Expanding IP Portfolio

    A Rapidly Expanding IP Portfolio Strong patent position covering portfolio / related technologies Backed by Freedom-To-Operate reports International coverage across U.S., EU and PCT(1) countries 80+ granted patents across 20+ countries Hundreds of additional patents filed and now in process Patents

  9. Slide 9: Clinical Development Programs

    Clinical Development Programs February 11, 2013 A precursor to Commercial Supply ContractsScope can include: Customization of a device Stability studies User studies Supply for clinical trialsCan range between six to 24 months in lengthCan have fees in the range of $3MM to $10MM Can include exclusiv

  10. Slide 10: Clinical Development Programs: A Unifill Syringe Program

    Some target drugs may have their own clinical development program. i.e. customizing finger flange for easy handling by a patient populationStability studies are a regulatory requirement Clinical Development Programs A Unifill Syringe Program February 11, 2013 Announced in December 2012 that another

  11. Slide 11: Clinical Development Programs: A Bolus Injection Device Program

    Clinical Development Programs Global pharmaceutical company selected Unilife's bolus injectors as preferred choice in final evaluation stage for multi-drug program. Customization to specific needs of each target drugExpect to enter into program this year for the lead drug targetA number of similar p

  12. Slide 12: Clinical Development Programs: Specialized Device for Targeted Organ Delivery

    Clinical Development Programs Developed a specialized device for target organ delivery for Global Pharmaceutical CompanySuccessfully completed $1.4MM initial stage of program last yearNext stage of program with additional revenues now being discussed with customer Specialized Device for Targeted Org

  13. Slide 13: Supply Contracts

    Supply Contracts Scope can include: Minor customizations Stability studies Commercial supplyTerms in the range of 7 to 10 years with recurring revenuesOpportunities forUpfront fees in the range of $1MM to $5MMCustomers paying for production equipment to guarantee capacityExclusivity and royalty fees

  14. Slide 14: Key Attributes of our Business Model

    Key Attributes of our Business Model February 11, 2013

  15. Slide 15: Financial Data Overview, Rich Wieland, CFO

    Financial Data Overview Rich Wieland Chief Financial Officer

  16. Slide 16: Financial Results

    Financial Results 2Q 2013 2Q 2012 Revenues $ 0.7M $ 0.9M Research & development expense $ 5.0M $ 5.3M Selling, general & administrative expense $ 8.3M $ 6.7M Net loss $ 14.6M $ 12.9M Net loss per share - diluted $ 0.19 $ 0.19 Adjusted net loss $ 9.7M $ 9.6M Adjusted net loss per share - diluted $ 0.

  17. Slide 17: Improving Operational Efficiencies

    Improving Operational Efficiencies Ongoing commitment to improve operational efficienciesContinuing to make progress towards this goal$1.6MM (13%) savings realized this quarter compared to Q420123.5% savings realized this quarter when compared against average quarterly operating expenses in fiscal y

  18. Slide 18: Dr. Ramin Mojdeh, EVP and COO

    Dr. Ramin Mojdeh Unilife EVP and COO NASDAQ (UNIS) and ASX (UNS)

  19. Slide 19: Questions

    Questions February 11, 2013

Unilife — Q2 FY2013 Earnings Presentation on 6ix